Can Insilico Medicine’s rentosertib slow FVC decline in Phase 3 IPF study?
Insilico Medicine starts Phase 3 testing of rentosertib in IPF, putting its AI-discovered TNIK inhibitor through a decisive 52-week trial.
Pharma & Biotech
Pharma & Biotech
Insilico rentosertib makes six proteomic aging clocks trend younger in IPF trial
A Nature Biotechnology analysis of 42 rentosertib-treated IPF trial participants found younger predicted biological-age profiles across six proteomic clocks, but researchers caution that the finding does not prove human aging was reversed.
Pharma & Biotech
A US$2.5bn AI drug alliance is taking shape, but what have Insilico and Bora actually agreed?
Insilico Medicine and Bora Pharmaceuticals propose an AI drug alliance worth over US$2.5 billion, but definitive agreements remain pending.
Pharma & Biotech
Insilico Medicine’s AI-originated IPF drug enters Phase 3, but the hardest test begins now
Find out how Insilico Medicine’s AI-originated rentosertib is entering Phase 3 testing for idiopathic pulmonary fibrosis.
Pharma & Biotech
Insilico Medicine secures Takeda collaboration to advance AI-designed drug candidates
Discover how Takeda’s $600 million Insilico Medicine collaboration could reshape AI drug discovery, candidate design and clinical translation.